Department of Pharmaco-epidemiology and Pharmaco-economy, University of Groningen, Groningen, The Netherlands.
Br J Clin Pharmacol. 2012 Jan;73(1):126-34. doi: 10.1111/j.1365-2125.2011.04081.x.
Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects.
The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development.
Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10-fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non-exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy.
The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re-uptake transporter (SERT) and because of selectivity for the 5-HT(2B) receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down-regulation of α₂-adrenoceptors or up-regulation of the pore forming α(1c) subunit.
在过去十年中,抗抑郁药的使用有所增加。有几项研究表明,母亲使用抗抑郁药与致畸作用之间可能存在关联。
使用 IADB.nl 药房处方数据库进行了一项队列研究,比较了儿童在子宫内暴露于抗抑郁药(三环类抗抑郁药、SSRIs、氟西汀或帕罗西汀)后与未暴露于抗抑郁药的情况下使用泻药和止泻药的情况。使用泻药和止泻药分别作为便秘和腹泻的替代指标,这可能与肠道神经系统(ENS)发育紊乱有关。
在妊娠第二和第三个三个月暴露于 SSRIs(主要是氟西汀和帕罗西汀)或在妊娠第一个三个月暴露于三环类抗抑郁药的儿童,更常使用泻药。在怀孕期间同时暴露于三环类抗抑郁药和 SSRIs 与使用泻药的风险增加 10 倍相关。与未暴露的儿童相比,在子宫内暴露于 SSRIs 与使用止泻药无关。相比之下,在怀孕期间任何时候暴露于三环类抗抑郁药的儿童使用止泻药的可能性明显更高。
妊娠第二和第三个三个月暴露于 SSRIs 后使用泻药增加,这可能是由于 5-羟色胺再摄取转运体(SERT)的抑制作用以及对影响 ENS 的 5-HT(2B)受体的选择性。在妊娠第一个三个月暴露于三环类抗抑郁药会导致泻药使用增加,这可能是通过抑制去甲肾上腺素转运体(NET)来实现的。在怀孕期间任何时候暴露于三环类抗抑郁药会导致腹泻使用增加,这可能是通过下调α₂-肾上腺素能受体或上调形成孔的 α(1c)亚基来实现的。